Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

Alexion Pharmaceuticals

Status and phase

Begins enrollment in 2 months

Phase 4

Conditions

Hypophosphatasia

Treatments

Drug: bortezomib

Drug: methotrexate

Drug: IVIg

Drug: rituximab

Drug: Folic Acid

Study type

Interventional

Funder types

Industry

Identifiers

NCT06015750

2022-502793-17 (EudraCT Number)

D8400C00001

AA-HPP-407 (Other Identifier)

Details and patient eligibility

About

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).

Full description

The administration of biological drugs to patients, especially for chronic conditions, carries a risk of eliciting anti-drug antibodies. Neutralizing antibodies can neutralize the clinical benefit of the agent. In postmarketing safety surveillance, some patients treated with asfotase alfa demonstrated an initial response, but subsequently recurrence and progression of disease. Consequently, the FDA requested a study to assess a potential serious risk of immune-mediated loss of effectiveness.

Enrollment

8 estimated patients

Sex

All

Ages

2 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Reoccurrence or worsening of rickets for at least the past 3 months in participants who showed an initial efficacy response to asfotase alfa after at least 6 months of continuous treatment and currently receiving asfotase alfa. RSS will be used to determine severity at Baseline.
Presence of ADAs, with or without NAbs, irrespective of their titers.
Confirmation by the TMB that both the clinical evidence and immunogenicity-mediated association noted above are present.
Female participants of childbearing potential and male participants with partners of childbearing potential must follow protocol-specified contraception guidance as described in Section 10.5.
Participant, or participant's legal guardian, is capable of signing informed consent or assent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol.

Exclusion criteria

Known history of human immunodeficiency virus (HIV) infection (evidenced by HIV type 1 or type 2 [HIV 1, HIV 2] antibody) or hepatitis B or C viral infection.
Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening.
Inability of the participant, or the participant's legal guardian, to provide informed consent.
Pregnant, breastfeeding, or intending to conceive during the course of the study.
Inability to travel to the clinic for specified visits during the Treatment Period caused by disease per se or logistics (does not apply to external travel restrictions).
The participant is at risk of reactivation or has an active significant viral infection such as hepatitis B, cytomegalovirus, herpes simplex, human polyomavirus (also known as John Cunningham [JC] virus), parvovirus, or Epstein Barr virus.
The participant is at risk of reactivation of tuberculosis or has regular contact (eg, in the household) with individuals who are being actively treated for tuberculosis.
The participant has had or is required to have any live vaccination within 1 month prior to enrollment.